These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16888847)

  • 21. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of sepsis in the critically ill patient: key aspects.
    Vincent JL
    Expert Opin Pharmacother; 2006 Oct; 7(15):2037-45. PubMed ID: 17020431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of drotrecogin alfa (activated) on resource use and implications for reimbursement.
    Dasta JF; Cooper LM
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):216S-222S. PubMed ID: 12492228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-cost sepsis drug forces pharmacists to weigh patients' future.
    Thompson CA
    Am J Health Syst Pharm; 2002 Apr; 59(8):692, 697. PubMed ID: 11977851
    [No Abstract]   [Full Text] [Related]  

  • 25. Drotrecogin alfa's impact on intensive care workload in real life practice: a propensity score approach.
    Riou França L; Payet S; Le Lay K; Launois R
    Value Health; 2008 Dec; 11(7):1051-60. PubMed ID: 18494757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Girbes AR; Polderman KH; Beishuizen A; van Zanten AR; Schultz MJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1265-6; author reply 1266. PubMed ID: 16796179
    [No Abstract]   [Full Text] [Related]  

  • 27. Combating mortality from severe sepsis.
    Ridley S
    Hosp Med; 2004 Oct; 65(10):580-1. PubMed ID: 15524335
    [No Abstract]   [Full Text] [Related]  

  • 28. Simplified pharmacoeconomics of critical care and severe sepsis.
    Ernst FR; Levy H; Qualy RL
    J Intensive Care Med; 2007; 22(5):283-93. PubMed ID: 17895486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in treating patients with severe sepsis. Role of drotrecogin alfa (activated).
    Kleinpell R
    Crit Care Nurse; 2003 Jun; 23(3):16-29; quiz 67-8. PubMed ID: 12830777
    [No Abstract]   [Full Text] [Related]  

  • 30. The Sepsis Saga: Consensus to Xigris.
    Dries DJ
    Air Med J; 2016; 35(4):194-6. PubMed ID: 27393750
    [No Abstract]   [Full Text] [Related]  

  • 31. "All in" for a huge pot: the PROWESS-SHOCK trial for refractory septic shock.
    Barie PS
    Surg Infect (Larchmt); 2007 Oct; 8(5):491-4. PubMed ID: 17999581
    [No Abstract]   [Full Text] [Related]  

  • 32. [Medical-economic evaluation of severe sepsis].
    Guidet B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():28-30. PubMed ID: 15359937
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of sepsis in the surgical intensive care unit.
    Carney DE; Matsushima K; Frankel HL
    Isr Med Assoc J; 2011 Nov; 13(11):694-9. PubMed ID: 22279706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated).
    Critical Care Society of South Africa Working Group
    S Afr Med J; 2003 Jun; 93(6):416-7. PubMed ID: 12916374
    [No Abstract]   [Full Text] [Related]  

  • 35. After Xigris, researchers look to new targets to combat sepsis.
    Williams SC
    Nat Med; 2012 Jul; 18(7):1001. PubMed ID: 22772543
    [No Abstract]   [Full Text] [Related]  

  • 36. The story of drotrecogin alfa - evidence-based or evidence-biased?
    Wiseman R; Blockman M
    S Afr Med J; 2011 Dec; 102(1):8. PubMed ID: 22273122
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of severe sepsis and multiple organ failure with activated protein C].
    Strøm JJ
    Ugeskr Laeger; 2004 Mar; 166(11):995. PubMed ID: 15049233
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug withdrawal sends critical care specialists back to basics.
    Mullard A
    Lancet; 2011 Nov; 378(9805):1769. PubMed ID: 22106464
    [No Abstract]   [Full Text] [Related]  

  • 39. RESOLVE-ing sepsis in children--not yet!
    Nadel S
    Crit Care; 2007; 11(3):138. PubMed ID: 17561989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.